Description

This episode focuses on liver cancer disparities in Europe. Liver cancer incidence disproportionately affects marginalized groups and deaths from liver cancer have continued to increase over the last decades. This episode addresses gaps in care, causes for inequities, and actions being taken at the EU level to improve liver cancer prevention.

The EASL Policy Dialogues are supported by CymaBay, Echosens, Grifols and Novo Nordisk. CymaBay, Echosens, Grifols and Novo Nordisk have had no input into the content of the EASL Policy Dialogues.

 

Speakers

  
Josep Llovet

Josep M. Llovet, MD, PhD is Professor of Medicine – Hepatic Oncology at University of Barcelona, Group leader and Professor of Research-ICREA in the Liver Unit, IDIBAPS-Hospital Clinic and Director of the Liver Cancer Program and Professor of Medicine at the Icahn School of Medicine at Mount Sinai, NY. He has devoted his career to the pathogenesis and treatment of liver cancer, publishing ~ 350 articles (~ 136,049 citations, h index: 134) and leading ~100 projects. He has been nominated as global Top-1% cited researcher (2014 to 2022) and nominated Editor in Chief of JHEP Reports (2024-29).
Richard Price

Richard Price is Head of Policy at European Cancer Organisation (ECO). He is a public policy professional with extensive experience in the healthcare and pharmaceutical sectors working as a policy manager in EU Affairs at ECO, policy and advocacy officer at the European Association of Hospital Pharmacists, and as policy advisor to the Pharmaceutical Society of Northern Ireland.

Log in to post comments